Answers are grounded in this paper and cite their sources.
Stride Velocity 95th Centile (SV95C) is the first wearable device-derived clinical outcome assessment (COA) to receive European Medicines Agency (EMA) qualification as a primary endpoint in ambulant patients with Duchenne muscular dystrophy (DMD) aged ≥4 years.
No takes yet. Share an insight, caveat, or question.
Rabbia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: